A multi-centre open label continuation study with subcutaneous D2E7 (adalimumab) for patients with rheumatoid arthritis who completed a preceding clinical study with D2E7 (adalimumab)
Phase of Trial: Phase III
Latest Information Update: 21 Nov 2011
At a glance
- Drugs Adalimumab (Primary)
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
- 21 Nov 2011 Actual patient number is 796 according to ClinicalTrials.gov.
- 21 Nov 2011 Actual end date (June 2006) added as reported by ClinicalTrials.gov.
- 28 Aug 2007 Status change from in progress to completed.